Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

PURPOSE Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. PATIENTS AND METHODS Fifty-nine adult patients (age 42 to 82 years) with relapsed or refractory CLL were enrolled onto a phase II study of lenalidomide and rituximab. Patients had received prior fludarabine-based therapy or chemoimmunotherapy. Rituximab (375 mg/m(2) intravenously) was administered weekly during cycle one and on day 1 of cycles three to 12. Lenalidomide was started on day 9 of cycle one at 10 mg orally and administered daily continuously. Each cycle was 28 days. Rituximab was administered for 12 cycles; lenalidomide could continue indefinitely if patients benefitted clinically. RESULTS The overall response rate was 66%, including 12% complete responses and 12% nodular partial remissions. Time to treatment failure was 17.4 months. Median overall survival has not been reached; estimated survival at 36 months is 71%. The most common grade 3 or 4 toxicity was neutropenia (73% of patients). Fourteen patients (24%) experienced a grade 3 to 4 infection or febrile episode. There was one episode of grade 3 tumor lysis; one patient experienced renal failure during the first cycle of therapy, and one venous thromboembolic event occurred during the study. CONCLUSION The combination of lenalidomide and rituximab is active in patients with recurrent CLL and warrants further investigation.

[1]  G. Morgan,et al.  A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. , 2012, Blood.

[2]  T. Kipps,et al.  Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study) , 2011 .

[3]  J. Reuben,et al.  Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. , 2011, Blood.

[4]  H. Döhner,et al.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Z. Estrov,et al.  Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia , 2011, Cancer.

[6]  E. Iannitto,et al.  Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study , 2011, British journal of haematology.

[7]  P. L. Bergsagel,et al.  Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Kantarjian,et al.  Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. , 2011, Blood.

[9]  M. Tucker,et al.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Kimby,et al.  Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) , 2010 .

[11]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[12]  A. Chanan-Khan,et al.  Management of patients with chronic lymphocytic leukemia treated with lenalidomide. , 2010, Clinical journal of oncology nursing.

[13]  A. Tsimberidou,et al.  Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options , 2010, Leukemia & lymphoma.

[14]  Lisa L. Smith,et al.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. , 2010, Blood.

[15]  P. Ganly,et al.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Dyer,et al.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Czuczman,et al.  Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics , 2010, Leukemia & lymphoma.

[18]  H. Kantarjian,et al.  Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia. , 2009 .

[19]  J. Gribben,et al.  Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug , 2009, Haematologica.

[20]  Thomas E. Hughes,et al.  Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia , 2009, Haematologica.

[21]  R. Schlenk,et al.  Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Rassenti,et al.  Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia , 2008, Leukemia.

[23]  K. Do,et al.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.

[24]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[25]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[26]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[27]  Z. Estrov,et al.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.

[28]  C. Pui,et al.  Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Lisa L. Smith,et al.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Cheson,et al.  Lenalidomide for the treatment of B-cell malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Czuczman,et al.  Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.

[32]  J. Zeldis,et al.  Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Deborah A. Bowen,et al.  Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features , 2007, Leukemia & lymphoma.

[34]  M. Czuczman,et al.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Kantarjian,et al.  Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[38]  J. Byrd,et al.  Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. , 2004, Clinical lymphoma.

[39]  E. Thiel,et al.  Remission Induction Using Alemtuzumab can Permit Chemotherapy-refractory Chronic Lymphocytic Leukemia (CLL) Patients to Undergo Allogeneic Stem Cell Transplantation , 2004, Leukemia & lymphoma.

[40]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[41]  H. Kantarjian,et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Grever,et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[44]  M. Hallek,et al.  Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. , 2005, Haematologica.